Yvonne Hui Sells 422 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Yvonne Hui sold 422 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $26.95, for a total transaction of $11,372.90. Following the completion of the transaction, the insider owned 30,281 shares of the company's stock, valued at approximately $816,072.95. This trade represents a 1.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Yvonne Hui also recently made the following trade(s):

• On Tuesday, July 15th, Yvonne Hui sold 307 shares of Phreesia stock. The stock was sold at an average price of $27.27, for a total transaction of $8,371.89.
• On Monday, July 7th, Yvonne Hui sold 571 shares of Phreesia stock. The stock was sold at an average price of $28.85, for a total transaction of $16,473.35.
• On Tuesday, June 10th, Yvonne Hui sold 582 shares of Phreesia stock. The stock was sold at an average price of $28.00, for a total transaction of $16,296.00.
• On Monday, April 21st, Yvonne Hui sold 993 shares of Phreesia stock. The stock was sold at an average price of $23.04, for a total transaction of $22,878.72.

Phreesia Price Performance

Shares of Phreesia stock traded up $0.68 during trading on Monday, hitting $26.16. 88,221 shares of the company's stock traded hands, compared to its average volume of 454,447. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95. The firm's fifty day moving average price is $26.50 and its 200 day moving average price is $26.41. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $30.53. The company has a market cap of $1.56 billion, a PE ratio of -35.27 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%. The business had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. During the same period in the prior year, the firm posted ($0.05) EPS. Phreesia's quarterly revenue was up 14.5% compared to the same quarter last year. Analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Citigroup restated a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. DA Davidson reduced their price objective on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Canaccord Genuity Group reduced their price objective on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a research report on Thursday, May 29th. KeyCorp raised their price objective on shares of Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a research report on Monday, July 14th. Finally, Wall Street Zen upgraded shares of Phreesia from a "hold" rating to a "buy" rating in a research report on Sunday, June 1st. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $32.27.

Hedge Funds Weigh In On Phreesia

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Phreesia by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock worth $126,177,000 after buying an additional 113,405 shares in the last quarter. Greenhouse Funds LLLP increased its position in shares of Phreesia by 2.9% during the 1st quarter. Greenhouse Funds LLLP now owns 2,956,910 shares of the company's stock worth $75,579,000 after purchasing an additional 83,018 shares in the last quarter. Champlain Investment Partners LLC increased its position in shares of Phreesia by 20.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock worth $75,312,000 after purchasing an additional 490,340 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Phreesia by 108.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock worth $67,606,000 after purchasing an additional 1,377,904 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Phreesia by 0.8% during the 4th quarter. Franklin Resources Inc. now owns 1,509,617 shares of the company's stock worth $37,982,000 after purchasing an additional 11,986 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.